Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Oncology Best Practices: The Next Frontier—Novel Combinations of Targeted Therapeutics

Release Date: February 27, 2009| Expiration Date: February 27, 2010
Dec 10, 2008, San Antonio, TX

Lecture Overview

The role of targeted biologic agents in the treatment of breast cancer is rapidly expanding and evolving. The armamentarium of agents in use or under investigation for HER2+ breast cancer is growing, and many of these new compounds have demonstrated efficacy even in patients who have progressed on prior HER2-targeted therapy. Investigation into mechanisms of resistance to conventional therapy has uncovered a number of potential targets, such as members of the PI3K/Akt pathway, and mammalian target of rapamycin (mTOR) inhibitors are in active clinical development. Angiogenic pathways are also the target of clinical investigation. Oncology Best Practices: The Next Frontier—Novel Combinations of Targeted Therapeutics is an educational activity designed to update medical oncologists on recent clinical trial data that might impact physician practice. The purpose of this program is to discuss strategies for integrating novel targeted agents into treatment regimens for patients with metastatic breast cancer (MBC), including as monotherapy or in combination with endocrine therapy, chemotherapy, or other biologic agents. The relevance of data reported at recent international oncology conferences to physician practice will also be discussed.

The purpose of this activity is to update physicians on the latest clinical data on the use of HER2-targeted agents and other novel signal transduction inhibitors in the treatment of patients with MBC.

This on-demand Webcast is from an event held in conjunction with the 31st Annual San Antonio Breast Cancer Symposium held on December 10-14, 2008, in San Antonio, TX.

This educational program is directed toward medical oncologists interested in reviewing the most recent clinical trial data on the treatment of breast cancer. Surgical and radiation oncologists, physician assistants, and other health care professionals interested in the treatment of breast cancer are also invited to participate.

Upon completion of this educational activity, you should be able to:

  • Evaluate the utility of novel antibodies and small-molecule tyrosine kinase inhibitors targeting HER2 for the treatment of HER2+ MBC
  • Review the efficacy and safety of mTOR inhibitors in combination regimens for the treatment of advanced/metastatic breast cancer

Accreditation and Credit Designation

Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Instructions for Participation

  1. Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3. View and study all Flash video presentations.
  4. Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.
  • You will be permitted 2 attempts to successfully complete the Posttest.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from the Oncology Best Practices: The Next Frontier—Novel Combinations of Targeted Therapeutics symposium have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

José Baselga, MD
Paid Consultant/Advisory Board – Exelixis, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Roche Pharmaceuticals; Research Funding – GlaxoSmithKline

Harold Burstein, MD, PhD
No relevant relationships to disclose

Debu Tripathy, MD
No relevant relationships to disclose

Commercial Support

An educational grant for this activity was provided by Wyeth Pharmaceuticals.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this learning activity are those of the presenters and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the presenters and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Privacy Policy

Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

©Copyright 2009 by Physicians’ Education Resource.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

All correspondence should be directed to:
Editor, Oncology Best Practices: The Next Frontier—Novel Combinations of Targeted Therapeutics
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Educational Grants

An educational grant for this activity was provided by:


  1. Wyeth Pharmaceuticals